Vironil-A 25 mg (Tablet)

Unit Price: ৳ 90.00 (1 x 10: ৳ 900.00)
Strip Price: ৳ 900.00

Medicine Details

Indications

  • Treatment of chronic hepatitis B virus infection in adults with compensated liver disease

Pharmacology

  • Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor
  • Tenofovir alafenamide is converted to tenofovir through hydrolysis primarily by carboxylesterase 1 (CES1) in primary hepatocytes
  • Tenofovir diphosphate inhibits HBV replication through incorporation into viral DNA by the HBV reverse transcriptase

Dosage & Administration

  • Recommended dosage of Tenofovir alafenamide is 25 mg (one tablet) taken orally once daily with food
  • No dosage adjustment of Tenofovir alafenamide is required in patients with estimated creatinine clearance greater than or equal to 15 ml per minute
  • Tenofovir alafenamide is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment

Interaction

  • Vironil-A is a substrate of P-glycoprotein (P-gp) and BCRP
  • Coadministration of Vironil-A with other drugs that inhibit P-gp and BCRP may increase the absorption & plasma concentration of Vironil-A
  • Coadministration of Vironil-A with drugs that strongly affect P-gp and BCRP activity may lead to changes in Vironil-A absorption

Side Effects

  • Headache
  • Stomach pain
  • Tiredness
  • Cough
  • Nausea
  • Back pain

Pregnancy & Lactation

  • Prevalence of birth defects in live births following first trimester exposure to TAF-containing regimens was 4.2%
  • It is not known whether Tenofovir alafenamide & its metabolites are present in human breast milk

Precautions & Warnings

  • Discontinuation of anti-hepatitis B therapy, including Vironil-A may result in severe acute exacerbations of hepatitis B
  • Due to the risk of development of HIV-1 resistance Vironil-A alone is not recommended for the treatment of HIV-1 infection
  • Postmarketing cases of renal impairment, including acute renal failure, have been reported with TAF-containing products

Overdose Effects

  • If overdose occurs, monitor patient for evidence of toxicity
  • Treatment of overdosage with Vironil-A consists of general supportive measures including monitoring of vital signs

Therapeutic Class

  • Hepatic viral infections (Hepatitis B)

Storage Conditions

  • Store below 30°C
  • Keep it in its original container
  • Protect from light
  • Keep out of children’s reach

Related Brands